全文获取类型
收费全文 | 30907篇 |
免费 | 1753篇 |
国内免费 | 115篇 |
专业分类
耳鼻咽喉 | 243篇 |
儿科学 | 712篇 |
妇产科学 | 568篇 |
基础医学 | 5626篇 |
口腔科学 | 525篇 |
临床医学 | 2692篇 |
内科学 | 5959篇 |
皮肤病学 | 1066篇 |
神经病学 | 3004篇 |
特种医学 | 1781篇 |
外科学 | 3958篇 |
综合类 | 113篇 |
一般理论 | 6篇 |
预防医学 | 1374篇 |
眼科学 | 462篇 |
药学 | 2603篇 |
中国医学 | 51篇 |
肿瘤学 | 2032篇 |
出版年
2023年 | 108篇 |
2022年 | 162篇 |
2021年 | 367篇 |
2020年 | 300篇 |
2019年 | 416篇 |
2018年 | 594篇 |
2017年 | 462篇 |
2016年 | 583篇 |
2015年 | 713篇 |
2014年 | 832篇 |
2013年 | 1099篇 |
2012年 | 1892篇 |
2011年 | 2002篇 |
2010年 | 1104篇 |
2009年 | 1016篇 |
2008年 | 1904篇 |
2007年 | 2010篇 |
2006年 | 1931篇 |
2005年 | 1909篇 |
2004年 | 1846篇 |
2003年 | 1834篇 |
2002年 | 1749篇 |
2001年 | 461篇 |
2000年 | 352篇 |
1999年 | 420篇 |
1998年 | 344篇 |
1997年 | 296篇 |
1996年 | 259篇 |
1995年 | 230篇 |
1994年 | 209篇 |
1993年 | 198篇 |
1992年 | 201篇 |
1991年 | 194篇 |
1990年 | 193篇 |
1989年 | 208篇 |
1988年 | 197篇 |
1987年 | 174篇 |
1986年 | 149篇 |
1985年 | 141篇 |
1984年 | 153篇 |
1983年 | 126篇 |
1982年 | 127篇 |
1981年 | 126篇 |
1980年 | 123篇 |
1979年 | 123篇 |
1978年 | 107篇 |
1977年 | 117篇 |
1975年 | 93篇 |
1974年 | 116篇 |
1973年 | 96篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
3.
4.
Erika Cecon Anna Ivanova Marine Luka Florence Gbahou Anne Friederich Jean‐Luc Guillaume Patrick Keller Klaus Knoch Raise Ahmad Philippe Delagrange Michele Solimena Ralf Jockers 《Journal of pineal research》2019,66(2)
Melatonin receptors play important roles in the regulation of circadian and seasonal rhythms, sleep, retinal functions, the immune system, depression, and type 2 diabetes development. Melatonin receptors are approved drug targets for insomnia, non‐24‐hour sleep‐wake disorders, and major depressive disorders. In mammals, two melatonin receptors (MTRs) exist, MT1 and MT2, belonging to the G protein‐coupled receptor (GPCR) superfamily. Similar to most other GPCRs, reliable antibodies recognizing melatonin receptors proved to be difficult to obtain. Here, we describe the development of the first monoclonal antibodies (mABs) for mouse MT1 and MT2. Purified antibodies were extensively characterized for specific reactivity with mouse, rat, and human MT1 and MT2 by Western blot, immunoprecipitation, immunofluorescence, and proximity ligation assay. Several mABs were specific for either mouse MT1 or MT2. None of the mABs cross‐reacted with rat MTRs, and some were able to react with human MTRs. The specificity of the selected mABs was validated by immunofluorescence microscopy in three established locations (retina, suprachiasmatic nuclei, pituitary gland) for MTR expression in mice using MTR‐KO mice as control. MT2 expression was not detected in mouse insulinoma MIN6 cells or pancreatic beta‐cells. Collectively, we report the first monoclonal antibodies recognizing recombinant and native mouse melatonin receptors that will be valuable tools for future studies. 相似文献
5.
6.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献7.
Frédéric Janvier Deborah Delaune Thomas Poyot Eric Valade Audrey Mérens Pierre E. Rollin Vincent Foissaud 《Emerging infectious diseases》2016,22(2):292-294
We evaluated RNA stability of Ebola virus in EDTA blood and urine samples collected from infected patients and stored in West Africa’s environmental conditions. In blood, RNA was stable for at least 18 days when initial cycle threshold values were <30, but in urine, RNA degradation occurred more quickly. 相似文献
8.
9.
10.